改良免疫细胞在肾移植受者中诱导长效调节性B淋巴细胞
一项1期临床试验随访10例肾移植前接受供者来源改良免疫细胞(MIC)输注的患者至移植后1080天,未出现供者特异性HLA抗体或急性排斥。接受最高剂量MIC并减少免疫抑制的4例患者体外对供者细胞无反应,过渡型B淋巴细胞数分别较12例长期存活者和4例操作耐受者高75倍和7倍(均P<0.001)。
要点
- 肾移植前输注供者来源MIC的患者至移植后1080天未出现供者特异性HLA抗体或急性排斥。
- 最高剂量MIC组过渡型B淋巴细胞数较长期存活者高75倍、较操作耐受者高7倍(均P<0.001)。
- 4例中3例其他调节性B细胞亚群升高并呈提示操作耐受的基因表达特征。
核心结论
- MIC输注后供者特异性免疫抑制持久,并与调节性B淋巴细胞显著增加相关。
- 供者来源MIC在移植前给予受者,可能对肾移植发挥有益作用。
研究设计与样本
- 1期临床试验(TOL-1,NCT02560220)中10例肾移植前接受MIC输注的患者随访至移植后1080天。
主要发现
- MIC治疗患者临床过程良好,未出现供者特异性HLA抗体或急性排斥。
- 移植前7天接受最高剂量MIC并减少免疫抑制的4例患者体外对供者血细胞无淋巴细胞反应性,而对第三方细胞反应性保留。
- 上述4例患者过渡型B淋巴细胞数较12例最小免疫抑制长期存活者高75倍、较4例操作耐受者高7倍(均P<0.001)。
- 4例中3例其他调节性B淋巴细胞亚群数量显著升高,并呈提示操作耐受的基因表达特征。
- MIC治疗患者B淋巴细胞清除后体外对供者血细胞的淋巴细胞反应性恢复,提示调节性B淋巴细胞在供者特异性无反应中起直接病理生理作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We recently demonstrated that donor-derived modified immune cells (MICs)-PBMCs that acquire immunosuppressive properties after a brief treatment-induced specific immunosuppression against the allogeneic donor when administered before kidney transplantation. We found up to a 68-fold increase in CD19 + CD24 hi CD38 hi transitional B lymphocytes compared with transplanted controls. METHODS: Ten patients from a phase 1 clinical trial who had received MIC infusions before kidney transplantation were followed to post-transplant day 1080. RESULTS: Patients treated with MICs had a favorable clinical course, showing no donor-specific human leukocyte antigen antibodies or acute rejections. The four patients who had received the highest dose of MICs 7 days before surgery and were on reduced immunosuppressive therapy showed an absence of in vitro lymphocyte reactivity against stimulatory donor blood cells, whereas reactivity against third party cells was preserved. In these patients, numbers of transitional B lymphocytes were 75-fold and seven-fold higher than in 12 long-term survivors on minimal immunosuppression and four operationally tolerant patients, respectively ( P <0.001 for both). In addition, we found significantly higher numbers of other regulatory B lymphocyte subsets and a gene expression signature suggestive of operational tolerance in three of four patients. In MIC-treated patients, in vitro lymphocyte reactivity against donor blood cells was restored after B lymphocyte depletion, suggesting a direct pathophysiologic role of regulatory B lymphocytes in donor-specific unresponsiveness. CONCLUSIONS: These results indicate that donor-specific immunosuppression after MIC infusion is long-lasting and associated with a striking increase in regulatory B lymphocytes. Donor-derived MICs appear to be an immunoregulatory cell population that when administered to recipients before transplantation, may exert a beneficial effect on kidney transplants. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: MIC Cell Therapy for Individualized Immunosuppression in Living Donor Kidney Transplant Recipients (TOL-1), NCT02560220.
引用
- Morath C, Schaier M, Ibrahim E, et al. Induction of Long-Lasting Regulatory B Lymphocytes by Modified Immune Cells in Kidney Transplant Recipients. J Am Soc Nephrol. 2022. PMID: 36137752. doi:10.1681/ASN.2022020210
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。